KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Treasury Shares (2016 - 2025)

Nektar Therapeutics (NKTR) has 13 years of Treasury Shares data on record, last reported at $552307.0 in Q2 2025.

  • For Q2 2025, Treasury Shares fell 93.33% year-over-year to $552307.0; the TTM value through Jun 2025 reached $552307.0, down 93.33%, while the annual FY2024 figure was $552307.0, 86.94% down from the prior year.
  • Treasury Shares reached $3.0 million in Q2 2025 per NKTR's latest filing, roughly flat from $3.0 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $9.9 million in Q4 2021 and bottomed at -$552307.0 in Q1 2024.
  • Average Treasury Shares over 4 years is $3.6 million, with a median of $552307.0 recorded in 2024.
  • The widest YoY moves for Treasury Shares: up 0.0% in 2025, down 0.0% in 2025.
  • A 2-year view of Treasury Shares shows it stood at $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $552307.0 in Q2 2025, $552307.0 in Q1 2025, and $552307.0 in Q4 2024.